The proven Zacks Rank system focuses on earnings estimates and estimate revisions to find winning stocks. Nevertheless, we know that our readers all have their own perspectives, so we are always looking at the latest trends in value, growth, and momentum to find strong picks.Considering these trends, value investing is clearly one of the most preferred ways to find strong stocks in any type of market. Value investors use fundamental analysis and traditional valuation metrics to find stocks that they believe ...

CORAL GABLES, Fla., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, today announced its inclusion in Forbes' esteemed list of America's Most Successful Small-Cap Companies for the year 2026. Catalyst has ranked an impressive 11 out of 100 companies on the list. “We are ho ...

Core Insights - Catalyst Pharmaceuticals, Inc. is launching the inaugural Catalyst Advocacy Scholars Summit in collaboration with The University of Notre Dame to enhance student engagement in the biopharmaceutical industry [1][2] - The program aims to provide students with an immersive experience in patient advocacy and the challenges of delivering medicine for rare diseases [1][2] - Catalyst Pharmaceuticals is recognized for its commitment to improving the lives of patients with rare diseases and has been acknowledged on Forbes and Deloitte lists for its success and growth [3] Group 1 - The Catalyst Advocacy Scholars Summit will take place from January 5 to 9, 2026, in Coral Gables, Florida, and will involve 12 selected students [2] - The program is designed to attract talented individuals to the biopharmaceutical sector and enhance patient focus within scientific education [2] - Catalyst Pharmaceuticals emphasizes its dedication to patient care and accessibility, providing comprehensive support services to ensure patients receive necessary treatments [3] Group 2 - Catalyst Pharmaceuticals has a strong U.S. presence, which is central to its commercial strategy, while also exploring opportunities for global expansion [3] - The company has a proven track record of bringing innovative therapies to market, focusing on in-licensing and commercialization [3] - Catalyst was recognized as one of America's Most Successful Mid-Cap Companies and one of North America's Fastest-Growing Companies in 2025 [3]

The exercise-and-sell transaction came as the rare disease drugmaker reported strong quarterly results. Jeffrey Del Carmen, Chief Commercial Officer of Catalyst Pharmaceuticals (CPRX +0.26%), exercised and immediately sold 10,983 shares of common stock on November 26, 2025, for a total value of approximately $256,200, as disclosed in this SEC Form 4 filing.Transaction summaryMetricValueShares sold10,983Transaction value~$256,200Post-transaction shares3,962Post-transaction value (direct ownership)~$92,800Tra ...

Investors interested in Medical - Drugs stocks are likely familiar with Catalyst Pharmaceutical (CPRX) and Daiichi Sankyo Co., Ltd. - Sponsored ADR (DSNKY) . But which of these two companies is the best option for those looking for undervalued stocks? Let's take a closer look.There are plenty of strategies for discovering value stocks, but we have found that pairing a strong Zacks Rank with an impressive grade in the Value category of our Style Scores system produces the best returns. The Zacks Rank favors ...

Shares of Catalyst Pharmaceutical (CPRX) have gained 6.8% over the past four weeks to close the last trading session at $24.19, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $34.5 indicates a potential upside of 42.6%.The average comprises eight short-term price targets ranging from a low of $32.00 to a high of $40.00, with a standard deviation of $2.67. While the lowest estim ...

CORAL GABLES, Fla., Dec. 15, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, today announced that Rich Daly, President and CEO of Catalyst, along with other members of Catalyst's management team, will present at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January ...

Group 1 - Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) is considered a cheap healthcare stock with a consensus Buy rating from all seven analysts covering it, indicating a potential upside of 48.75% from its current price of $35 [1] - The company is focused on advancing education in the oncology space and accelerating organic growth by targeting patients at various stages of the diagnostic journey, despite competition in the epilepsy market [3] - Catalyst Pharmaceuticals is a commercial-stage biopharmaceutical company based in Florida, founded in 2002, and offers treatments such as Firdapse, Fycompa, Ruzurgi, and AGAMREE for life-threatening diseases [4] Group 2 - On November 26, the Chief Commercial Officer of Catalyst Pharmaceuticals, Jeffrey Del Carmen, sold 10,983 shares of common stock for approximately $256,244, leaving him with 3,962 shares [2]

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...

Summary of Catalyst Pharmaceuticals Conference Call Company Overview - **Company**: Catalyst Pharmaceuticals (NasdaqCM: CPRX) - **Key Products**: Agamree and Firdapse - **Focus**: Rare diseases and orphan drug development Key Points Business Development and Licensing - Catalyst Pharmaceuticals is focused on business development (BD) and licensing as core components of its strategy, particularly concerning Firdapse's intellectual property (IP) resolution before significant capital deployment [4][5][18] - The company has assessed over 100 opportunities since the beginning of the year, indicating a proactive approach to identifying potential acquisitions [6][7] Financial Position - Catalyst has approximately $689 million in cash and no funded debt, positioning it as a strong bidder in the market [9] - The company is cautious about entering bidding wars with larger players and aims to focus on opportunities that are immediately accretive or nearly so [5][9] Product Performance and Market Potential - Firdapse has the potential to exceed $500 million in revenue, with a focus on lifecycle management to optimize patient engagement and product usage [11][12] - Agamree is showing promising patient sourcing, with 45% from Emflaza, 45% from Prednisone, and 10% naive patients, indicating strong market acceptance [29][30] - The addressable market for steroids is estimated to be above $1 billion, with the potential for significant growth if the product proves effective in clinical trials [33][34] Clinical Trials and Research - The SUMMIT trial is critical for validating the efficacy of Agamree, with expectations of positive outcomes based on previous trials [35][36] - The company is conducting a phase one study to determine the immunosuppressive dose of Agamree, which could open new therapeutic avenues [15][17] Intellectual Property and Litigation - Catalyst is actively defending its IP for Firdapse, having settled with three out of four defendants in ongoing litigation [18][50] - The company believes its patent estate is robust, which is crucial for maintaining market exclusivity [50][69] Market Dynamics and Competitive Landscape - The company is facing generic competition for Fycompa, but brand stickiness is reportedly holding up better than expected [63][64] - The introduction of generics has not significantly dented Firdapse's business, indicating strong market positioning and patient loyalty [70] Future Outlook and Strategic Focus - Catalyst aims to expand its portfolio into other rare conditions requiring long-term steroid use, focusing on patient populations that can benefit most from its products [46][48] - The company is also exploring opportunities in the oncology space, particularly for cancer-associated LEMS patients, which could enhance its market reach [55][76] Capital Allocation - A $200 million share repurchase program has been authorized, signaling confidence in the company's financial health while maintaining flexibility for business development [66][67] - The company is committed to balancing capital allocation between share buybacks and potential acquisitions [67] Payer Coverage and Market Access - Payer coverage for Agamree is improving, with nearly 90% of prescriptions being approved, indicating growing acceptance among insurers [39][40] - The company is working to streamline the process for patients to access its therapies, which is critical for maintaining market share [39][40] Conclusion Catalyst Pharmaceuticals is strategically positioned in the rare disease market with a strong financial foundation and a focus on innovative product development. The company is actively managing its IP, exploring new market opportunities, and optimizing its existing product lines to drive growth and enhance shareholder value.